Systemic lupus erythematosus-related interstitial lung disease

Current Rheumatology Reviews

Volumn 6, Issue 2, 2010, Pages 99-107

  Mittoo, Shikha ^a   Fischer, Aryeh ^b   Strand, Vibeke ^c   Meehan, Richard ^b   Swigris, Jeffrey J ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b DEPARTMENT OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Interstitial lung disease; Lupus; Review

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ARTICLE; BRONCHOSCOPY; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG MEGADOSE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; LUNG BIOPSY; LUNG FUNCTION TEST; LUNG LAVAGE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 77956596355     PISSN: 15733971     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339710791330759     Document Type: Article

References (89)

1. Ward MM. Prevalence of physician-diagnosed systemic lupus erythematosus in the United States: Results from the third national health and nutrition examination survey. J Womens Health (Larchmt) 2004; 13(6): 713-8.
2. Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: Estimates obtained using hospitalization data. Arthritis Rheum 2007; 56(6): 2092-4.
3. Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2002; 16(5): 847-58.
4. Pines A, Kaplinsky N, Olchovsky D, Rozenman J, Frankl O. Pleuro-pulmonary manifestations of systemic lupus erythematosus: Clinical features of its subgroups. Prognostic and therapeutic implications. Chest 1985; 88(1): 129-35.
5. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: Idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175(7): 705-11.
6. Quadrelli S, Alvarez C, Arce S, et al. Pulmonary involvement of systemic lupus erythematosus: Analysis of 90 necropsies. Lupus 2009; 18(12): 1053-60.
7. Estes D, Christian CL. The natural history of systemic lupus erythematosus by prospective analysis. Medicine (Baltimore) 1971; 50(2): 85-95.
8. Eisenberg H, Dubois EL, Sherwin RP, Balchum OJ. Diffuse interstitial lung disease in systemic lupus erythematosus. Ann Intern Med 1973; 79(1): 37-45.
9. Jacobsen S, Petersen J, Ullman S, et al. A multicentre study of 513 Danish patients with systemic lupus erythematosus. I. Disease manifestations and analyses of clinical subsets. Clin Rheumatol 1988; 17(6): 468-77.
10. Nakano M, Hasegawa H, Takada T, et al. Pulmonary diffusion capacity in patients with systemic lupus erythematosus. Respirology 2002; 7(1): 45-9.
11. Lee SS, Singh S, Link K, Petri M. High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. Semin Arthritis Rheum 2008; 38(1): 41-54.
12. Bertoli AM, Vila LM, Apte M, et al. Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage. Lupus 2007; 16(6): 410-7.
13. Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993; 72(2): 113-24.
14. Purice S, Tudor A, Gheorghiu M, et al. Pulmonary involvement in systemic lupus erythematosus. Med Internet 1987; 25(4): 227-32.
15. Alarcon-Segovia D, Deleze M, Oria CV, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989; 68(6): 353-65.
16. Gross M, Esterly JR, Earle RH. Pulmonary alterations in systemic lupus erythematosus. Am Rev Respir Dis 1972; 105(4): 572-7.
17. Haupt HM, Moore GW, Hutchins GM. The lung in systemic lupus erythematosus. Analysis of the pathologic changes in 120 patients. Am J Med 1981; 71(5): 791-8.
18. Ooi GC, Ngan H, Peh WC, Mok MY, Ip M. Systemic lupus erythematosus patients with respiratory symptoms: The value of HRCT. Clin Radiol 1997; 52(10): 775-81.
19. Silberstein SL, Barland P, Grayzel AI, Koerner SK. Pulmonary dysfunction in systemic lupus erythematosus:prevalence classification and correlation with other organ involvement. J Rheumatol 1980; 7(2): 187-95.
20. Andonopoulos AP, Constantopoulos SH, Galanopoulou V, Drosos AA, Acritidis NC, Moutsopoulos HM. Pulmonary function of nonsmoking patients with systemic lupus erythematosus. Chest 1988; 94(2): 312-5.
21. Sant SM, Doran M, Fenelon HM, Breatnach ES. Pleuropulmonary abnormalities in patients with systemic lupus erythematosus: assessment with high resolution computed tomography, chest radiography and pulmonary function tests. Clin Exp Rheumatol 1997; 15(5): 507-13.
22. Petri M. Hopkins Lupus Cohort. 1999 update. Rheum Dis Clin North Am 2000; 26(2): 199-213, v.
23. Ward MM, Polisson RP. A meta-analysis of the clinical manifestations of older-onset systemic lupus erythematosus. Arthritis Rheum 1989; 32(10): 1226-32.
24. Lilleby V, Aalokken TM, Johansen B, Forre O. Pulmonary involvement in patients with childhood-onset systemic lupus erythematosus. Clin Exp Rheumatol 2006; 24(2): 203-8.
25. Groen H, ter Borg EJ, Postma DS, Wouda AA, van der Mark TW, Kallenberg CG. Pulmonary function in systemic lupus erythematosus is related to distinct clinical, serologic, and nailfold capillary patterns. Am J Med 1992; 93(6): 619-27.
26. Boulware DW, Hedgpeth MT. Lupus pneumonitis and anti- SSA(Ro) antibodies. J Rheumatol 1989; 16(4): 479-81.
27. Yasuma M, Takasaki Y, Matsumoto K, Kodama A, Hashimoto H, Hirose S. Clinical significance of IgG anti-Sm antibodies in patients with systemic lupus erythematosus. J Rheumatol 1990; 17(4): 469-75.
28. Yee CS, Hussein H, Skan J, Bowman S, Situnayake D, Gordon C. Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. Rheumatology (Oxford) 2003; 42(2): 276-9.
29. Weinrib L, Sharma OP, Quismorio FP Jr. A long-term study of interstitial lung disease in systemic lupus erythematosus. Semin Arthritis Rheum 1990; 20(1): 48-56.
30. Dubois EL, Tuffanelli DL. Clinical manifestations of systemic lupus erythematosus. computer analysis of 520 cases. JAMA 1964; 190: 104-11.
31. Kinoshita F, Hamano H, Harada H, et al. Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: Comparison with HRCT. Respir Med 2004; 98(11): 1131-7.
32. Yamane K, Inh H, Kubo M, et al. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. J Rheumatol 2000; 27(4): 930-4.
33. Stahel R. A., Gilks WR, Lehmann HP, Schenker T. Third international workshop on lung tumor and differentiation antigens: Overview of the results of the central data analysis. Int J Cancer Suppl 1994; 8: 6-26.
34. Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002; 165(3): 378-81.
35. Asano Y, Ihn H, Yamane K, et al. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. Arthritis Rheum 2001; 44(6): 1363-9.
36. Honda Y, Kuroki Y, Matsuura E, et al. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995; 152(6 Pt 1): 1860-6.
37. Yanaba K, Hasegawa M, Takehara K, Sato S. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 2004; 31(6): 1112-20.
38. Matthay RA, Schwarz MI, Petty TL, et al. Pulmonary manifestations of systemic lupus erythematosus: Review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore) 1975; 54(5): 397-409.
39. Wells A, Denton C. Pulmonary Involvement in Systemic Autoimmune Diseases. The Netherlands: Elsevier 2004.
40. Purnell DC, Baggenstoss AH, Olsen AM. Pulmonary lesions in disseminated lupus erythematosus. Ann Intern Med 1955; 42(3): 619-28.
41. Rodriguez-Iturbe B, Garcia R, Rubio L, Serrano H. Immunohisto-logic findings in the lung in systemic lupus erythematosus. Arch Pathol Lab Med 1977; 101(7): 342-4.
42. Myers JL, Katzenstein AA. Microangiitis in lupus-induced pulmonary hemorrhage. Am J Clin Pathol 1986; 85(5): 552-6.
43. Churg A, Franklin W, Chan KL, Kopp E, Carrington CB. Pulmonary hemorrhage and immune-complex deposition in the lung. Complications in a patient with systemic lupus erythematosus. Arch Pathol Lab Med 1980; 104(7): 388-91.
44. Kim EA, Lee KS, Johkoh T, et al. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics 2002; 22: S151-65.
45. Groen H, Aslander M, Bootsma H, van der Mark TW, Kallenberg CG, Postma DS. Bronchoalveolar lavage cell analysis and lung function impairment in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1993; 94(1): 127-33.
46. Witt C, Dorner T, Hiepe F, Borges AC, Fietze I, Baumann G. Diagnosis of alveolitis in interstitial lung manifestation in connective tissue diseases: Importance of late inspiratory crackles, 67 gallium scan and bronchoalveolar lavage. Lupus 1996; 5(6): 606-12.
47. Romagnani S. Immunologic influences on allergy and the TH1/TH2 balance. J Allergy Clin Immunol 2004; 113(3): 395-400.
48. Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: Downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 1995; 21(5): 791-808.
49. Deguchi Y, Kishimoto S. Spontaneous activation of transforming growth factor-beta gene transcription in broncho-alveolar mononuclear cells of individuals with systemic autoimmune diseases with lung involvement. Lupus 1991; 1(1): 27-30.
50. Deguchi Y, Kishimoto S. Tumour necrosis factor/cachectin plays a key role in autoimmune pulmonary inflammation in lupus-prone mice. Clin Exp Immunol 1991; 85(3): 392-5.
51. ter Borg EJ, Groen H, Horst G, Limburg PC, Wouda AA, Kallenberg CG. Clinical associations of antiribonucleoprotein antibodies in patients with systemic lupus erythematosus. Semin Arthritis Rheum 1990; 20(3): 164-73.
52. Kobayashi O. An electron microscopic study of the pulmonary alveolar capillaries in idiopathic interstitial pneumonia and lungs of collagen vascular diseases. Nihon Kyobu Shikkan Gakkai Zasshi 1991; 29(8): 1007-16.
53. Yum HK, Kim ES, Ok KS, Lee HK, Choi SJ. Lymphocytic interstitial pneumonitis associated with Epstein-Barr virus in systemic lupus erythematosus and Sjogren's syndrome. Complete remission with corticosteriod and cyclophosphamide. Korean J Intern Med 2002; 17(3): 198-203.
54. Swigris JJ, Fischer A, Gillis J, Meehan RT, Brown KK. Pulmonary and thrombotic manifestations of systemic lupus erythematosus. Chest 2008; 133(1): 271-80.
55. Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004; 44(6): 585-96.
56. Min JK, Hong YS, Park SH, et al. Bronchiolitis obliterans organizing pneumonia as an initial manifestation in patients with systemic lupus erythematosus. J Rheumatol 1997; 24(11): 2254-7.
57. Gammon RB, Bridges TA, al-Nezir H, Alexander CB, Kennedy JI Jr. Bronchiolitis obliterans organizing pneumonia associated with systemic lupus erythematosus. Chest 1992; 102(4): 1171-4.
58. Schattner A, Aviel-Ronen S, Mark EJ. Accelerated usual interstitial pneumonitis, anti-DNA antibodies and hypocomplementemia. J Intern Med 2003; 254(2): 193-6.
59. Filipek MS, Thompson ME, Wang PL, Gosselin MV. Lymphocytic interstitial pneumonitis in a patient with systemic lupus erythematosus: Radiographic and high-resolution CT findings. J Thorac Imaging 2004; 19(3): 200-3.
60. Benisch B, Peison B. The association of lymphocytic interstitial pneumonia and systemic lupus erythematosus. Mt Sinai J Med 1979; 46(4): 398-41.
61. Otsuka F, Amano T, Hashimoto N, et al. Bronchiolitis obliterans organizing pneumonia associated with systemic lupus erythematosus with antiphospholipid antibody. Intern Med 1996; 35(4): 341-4.
62. Fischer A, Dubois RM. Lung systemic lupus erythematosus. 5th ed. San Diego, CA: Elsevier 2010.
63. Mittoo S, Gelber AC, Christopher-Stine L, Horton MR, Lechtzin N, Danoff SK. Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respir Med 2009; 103(8): 1152-8.
64. Takada H, Saito Y, Nomura A, et al. Bronchiolitis obliterans organizing pneumonia as an initial manifestation in systemic lupus erythematosus. Pediatr Pulmonol 2005; 40(3): 257-60.
65. Fenlon HM, Doran M, Sant SM, Breatnach E. High-resolution chest CT in systemic lupus erythematosus. Am J Roentgenol 1996; 166(2): 301-7.
66. Cheema GS, Quismorio FP Jr. Interstitial lung disease in systemic lupus erythematosus. Curr Opin Pulm Med 2000; 6(5): 424-9.
67. Keane MP, Lynch JP 3rd. Pleuropulmonary manifestations of systemic lupus erythematosus. Thorax 2000; 55(2): 159-66.
68. Holgate ST, Glass DN, Haslam P, Maini RN, Turner-Warwick M. Respiratory involvement in systemic lupus erythematosus. A clinical and immunological study. Clin Exp Immunol 1976; 24(3): 385-95.
69. Zamora MR, Warner ML, Tuder R, Schwarz MI. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore) 1997; 76(3): 192-202.
70. Pallis M, Hopkinson N, Powell R. Nailfold capillary density as a possible indicator of pulmonary capillary loss in systemic lupus erythematosus but not in mixed connective tissue disease. J Rheumatol 1991; 18(10): 1532-6.
71. Manoussakis MN, Georgopoulou C, Zintzaras E, et al. Sjogren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjogren's syndrome. Arthritis Rheum 2004; 50(3): 882-91.
72. Xu D, Tian X, Zhang W, Zhang X, Liu B, Zhang F. Sjogren's syndrome-onset lupus patients have distinctive clinical manifestations and benign prognosis: A case-control study. Lupus; 19(2): 197-200.
73. Mukerji B, Alpert MA, Hardin JG. When the lungs are involved by connective tissue disease. Postgrad Med 1993; 94(5): 147-52, 154, 157-8.
74. White B. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 2003; 29(2): 371-90.
75. Orens JB, Martinez FJ, Lynch JP 3rd. Pleuropulmonary manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am 1994; 20(1): 159-93.
76. Wells AU. High-resolution computed tomography and scleroderma lung disease. Rheumatology (Oxford) 2008; 47(Suppl 5): v59-61.
77. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354(25): 2655-66.
78. Bankier AA, Kiener HP, Wiesmayr MN, et al. Discrete lung involvement in systemic lupus erythematosus: CT assessment. Radiology 1995; 196(3): 835-40.
79. Murin S, Wiedemann HP, Matthay RA. Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med 1998; 19(4): 641-65, viii.
80. Silver RM, Miller KS, Kinsella MB, Smith EA, Schabel SI. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990; 88(5): 470-6.
81. Strange C, Bolster MB, Roth MD, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008; 177(1): 91-8.
82. Goh NS, Veeraraghavan S, Desai SR, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease is not predictive of disease progression. Arthritis Rheum 2007; 56(6): 2005-12.
83. Schnabel A, Reuter M, Gross WL. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998; 41(7): 1215-20.
84. Fink SD, Kremer JM. Successful treatment of interstitial lung disease in systemic lupus erythematosus with methotrexate. J Rheumatol 1995; 22(5): 967-9.
85. Eiser AR, Shanies HM. Treatment of lupus interstitial lung disease with intravenous cyclophosphamide. Arthritis Rheum 1994; 37(3): 428-31.
86. Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci 2009; 337(5): 329-35.
87. Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006; 130(1): 30-6.
88. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54(8): 2550-7.
89. Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996; 35(3): 248-54.